Literature DB >> 17254019

FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta.

Junichi Shioi1, Anastasios Georgakopoulos, Pankaj Mehta, Zen Kouchi, Claudia M Litterst, Lia Baki, Nikolaos K Robakis.   

Abstract

Strong support for a primary causative role of the Abeta peptides in the development of Alzheimer's disease (AD) neurodegeneration derives from reports that presenilin familial AD (FAD) mutants alter amyloid precursor protein processing, thus increasing production of neurotoxic Abeta 1-42 (Abeta 42). This effect of FAD mutants is also reflected in an increased ratio of peptides Abeta 42 over Abeta 1-40 (Abeta 40). In the present study, we show that several presenilin 1 FAD mutants failed to increase production of Abeta 42 or the Abeta 42/40 ratio. Our data suggest that the mechanism by which FAD mutations promote neurodegeneration and AD may be independent of their effects on Abeta production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17254019     DOI: 10.1111/j.1471-4159.2006.04391.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  41 in total

1.  Critical role of intraneuronal Aβ in Alzheimer's disease: technical challenges in studying intracellular Aβ.

Authors:  Gunnar K Gouras; Katarina Willén; Davide Tampellini
Journal:  Life Sci       Date:  2012-06-19       Impact factor: 5.037

Review 2.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

3.  Pathology's new role: defining disease process and protective responses.

Authors:  George Perry; Rudy J Castellani; Paula I Moreira; Hyoung-Gon Lee; Xiongwei Zhu; Mark A Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

4.  Presenilin 1 mutations influence processing and trafficking of the ApoE receptor apoER2.

Authors:  Wei Wang; Andrea M Moerman-Herzog; Arthur Slaton; Steven W Barger
Journal:  Neurobiol Aging       Date:  2016-10-11       Impact factor: 4.673

5.  Defective Transcytosis of APP and Lipoproteins in Human iPSC-Derived Neurons with Familial Alzheimer's Disease Mutations.

Authors:  Grace Woodruff; Sol M Reyna; Mariah Dunlap; Rik Van Der Kant; Julia A Callender; Jessica E Young; Elizabeth A Roberts; Lawrence S B Goldstein
Journal:  Cell Rep       Date:  2016-10-11       Impact factor: 9.423

6.  Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.

Authors:  Alex E Roher; Chera L Maarouf; Michael Malek-Ahmadi; Jeffrey Wilson; Tyler A Kokjohn; Ian D Daugs; Charisse M Whiteside; Walter M Kalback; Mimi P Macias; Sandra A Jacobson; Marwan N Sabbagh; Bernardino Ghetti; Thomas G Beach
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 7.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

Review 8.  Amyloid-beta immunisation for Alzheimer's disease.

Authors:  Thomas Wisniewski; Uwe Konietzko
Journal:  Lancet Neurol       Date:  2008-07-28       Impact factor: 44.182

Review 9.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

Review 10.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.